Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:HSTONASDAQ:ONCSNASDAQ:PRFXNASDAQ:XCUR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSTOHistogen$0.35+0.3%$0.38$0.05▼$1.05$1.50M0.9221,297 shs1,034 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsPRFXPainReform$0.81-3.5%$1.69$0.69▼$26.41$1.64M0.53116,004 shs13,357 shsXCURExicure$0.51+0.6%$0.62$0.36▼$1.50$4.43M1.31378,068 shs19,086 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSTOHistogen0.00%-29.98%-12.48%-5.38%-61.64%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-68.50%PRFXPainReform-2.08%-5.71%-53.38%-58.46%-85.15%XCURExicure-1.17%-12.06%-15.52%-3.31%-44.55%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/AN/AN/AN/AXCURExicure3.1338 of 5 stars0.05.00.04.71.81.71.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSTOHistogenN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AXCURExicureN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSTOHistogen$3.77M0.40N/AN/A$3.13 per share0.11ONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/APRFXPainReformN/AN/AN/AN/A$4.65 per shareN/AXCURExicure$28.83M0.15N/AN/A$3.00 per share0.17Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSTOHistogen-$10.62M-$2.81N/A∞N/A-65,142.11%-136.13%-90.87%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/APRFXPainReform-$9.34MN/A0.00∞N/AN/AN/AN/A5/20/2024 (Estimated)XCURExicure-$2.58M$1.680.30∞N/AN/AN/AN/A7/12/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSTOHistogenN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSTOHistogenN/A4.054.05ONCSOncoSec MedicalN/A0.890.89PRFXPainReformN/A4.074.07XCURExicureN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSTOHistogenN/AONCSOncoSec Medical8.69%PRFXPainReform37.28%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipHSTOHistogen3.30%ONCSOncoSec Medical1.32%PRFXPainReform34.40%XCURExicure3.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableHSTOHistogen74.27 million4.13 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionablePRFXPainReform72.03 million1.33 millionNot OptionableXCURExicure78.65 million8.31 millionNot OptionablePRFX, XCUR, ONCS, and HSTO HeadlinesSourceHeadlineExicure faces Nasdaq non-compliance over delayed filinginvesting.com - April 24 at 5:47 PMExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Kbusinesswire.com - April 22 at 4:01 PMExicure gets grant for liposomal particles for gene regulation with spherical geometrypharmaceutical-technology.com - April 18 at 9:05 AMExicure (NASDAQ:XCUR) Shares Down 8.7% americanbankingnews.com - April 18 at 1:34 AMExicure Stock (NASDAQ:XCUR), Short Interest Reportbenzinga.com - February 22 at 7:55 AMExicure inks licensing deal for one of its remaining therapieschicagobusiness.com - February 12 at 7:43 AMWhy FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com - February 6 at 2:15 PMWhy Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarketmsn.com - February 6 at 9:44 AMExicure Inc Announces Licensing Patents for Therapeutic Advancementmsn.com - February 6 at 9:15 AMExicure, Inc. and Bluejay Therapeutics Inc. Enter…pharmiweb.com - February 5 at 10:23 PMExicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis Treatmentmarketwatch.com - February 5 at 5:22 PMExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitisfinance.yahoo.com - February 5 at 5:22 PMBest Undervalued Stocks for February 2024msn.com - February 1 at 1:04 PMExicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo Financeca.finance.yahoo.com - December 16 at 8:49 AMWhy Is Exicure (XCUR) Stock Up 57% Today?investorplace.com - December 8 at 10:01 AMExicure: Nonreliance On Previously Issued Financial Statements Or A Related Audit Report Or Completed Interim Reviewcbonds.com - December 3 at 8:28 AMExicure receives Nasdaq delinquency notice on late filing of its form 10-Qmsn.com - November 28 at 5:18 PMExicure Inc XCURmorningstar.com - November 9 at 1:25 PMLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Dropfinance.yahoo.com - August 29 at 7:04 AMExicure names new CEO, CFO, directors in wake of resignationsmsn.com - August 23 at 4:05 PMExicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)finance.yahoo.com - August 15 at 7:28 AMExicure: Substantial Financing Needed to Continue Operationsmarketwatch.com - August 11 at 5:38 PMExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updatebusinesswire.com - August 11 at 5:38 PMExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - July 14 at 6:09 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsHistogenNASDAQ:HSTOHistogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.PainReformNASDAQ:PRFXPainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.ExicureNASDAQ:XCURExicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.